Skip to content
Buy This GLP
← Research
Evidence

Do GLP-1 Drugs Affect Blood Pressure? What Trials Found

Across 32 trials, tirzepatide cut hypertension-related events by 60% and more than doubled hypotension-related ones. Hypotension-related events also increased in the higher-dose analysis.

Editorial profile: Wesley JenkinsBuy This GLP Editorial Team7 min read
tirzepatide — hypertension eventstirzepatide — hypotension eventssemaglutide — hypertension eventssemaglutide — hypotension events1.0

In a review of 32 randomized trials with 47,332 participants, tirzepatide was associated with fewer hypertension-related adverse events and more hypotension-related adverse events than the comparators [1]. The NHANES blood pressure analysis used a different approach and included only 45 people who reported using a GLP-1 drug. The trial review counted reported events, while the survey analysis examined blood pressure measurements.

A separate analysis of three SURMOUNT outcomes evaluated weight, measured blood pressure and non-HDL cholesterol together. Across trials, 22% to 34% of tirzepatide participants and 1% to 3% of placebo participants met all three targets when the weight-loss threshold was at least 15% [2].

What was counted

The meta-analysis included 32 randomized trials with 47,332 participants treated for type 2 diabetes or obesity [1]. It pooled reports of hypertension- and hypotension-related events that occurred during treatment.

The trade

Tirzepatide was associated with a lower risk of hypertension-related events, RR 0.40, 95% CI 0.26 to 0.60, p<0.001. That is a large reduction and it is the kind of finding that gets quoted alone.

It was also associated with more hypotension-related events, RR 2.45, 95% CI 1.35 to 4.45, p=0.003. At higher doses that rose to RR 2.58, 95% CI 1.38 to 4.81. The review counted reported adverse events and did not estimate the amount by which blood pressure changed.

What the review found for semaglutide

For semaglutide the hypertension-related risk ratio was 0.81, 95% CI 0.57 to 1.15, and the hypotension-related risk ratio 1.39, 95% CI 0.81 to 2.36. Both intervals include no effect, so the analysis did not establish a difference for either event category.

Comparing prices for a prescription

Across 142 sellers publishing prices for both injections, tirzepatide costs a median of $70 more per month. The price check helps compare quotes for the medication you were prescribed. The latest price check on record was November 2026. The trial review did not test whether paying more changes your individual risk.

The GLP-1 side-effects guide covers additional outcomes that belong in a discussion with your prescriber. This review examined only blood-pressure-related events.

What the design cannot tell you

How big any of this is in absolute terms. Risk ratios describe proportional change and the abstract gives no event rates. So a reader cannot tell whether a 2.45-fold increase means a rare thing became less rare, or a common thing became commoner. Without those numbers the practical size of the trade is unknown.

And adverse-event capture varies between trials — what one study records as a hypotension-related event another may not record at all. Pooling 32 trials averages over that inconsistency rather than resolving it.

Frequently asked

Does tirzepatide lower blood pressure?
It was associated with 60% fewer hypertension-related adverse events, RR 0.40 with a 95% CI of 0.26 to 0.60. The outcome is recorded events rather than measured pressure, so no millimeter figure comes from this analysis.
Is the hypotension risk serious?
The relative increase was substantial — RR 2.45, rising to 2.58 at higher doses — but the abstract gives no event rates, so how common these events were in absolute terms is not established here.
What did the review find for semaglutide?
Its intervals for both outcomes include no effect: RR 0.81 for hypertension events and 1.39 for hypotension. Both confidence intervals are wide enough to include no difference. The review does not establish why the estimates differed.
What should I do if I take blood pressure medication?
Ask your prescriber how to monitor your blood pressure during treatment and when to report dizziness or other symptoms.

Sources

  1. [1] Chen QX, et al. (2026). Effect of tirzepatide and semaglutide on blood pressure: A systematic review and meta-analysis Endocrine. PMID 42603240
  2. [2] Sattar N, et al. (2026). Achieving the triple endpoint of body weight reduction thresholds, systolic blood pressure reduction ≥5 mmHg and non-HDL cholesterol <130 mg/dL with tirzepatide in people with obesity: A post hoc analysis from the SURMOUNT trials PLOS ONE. PMID 42594122

Where to get it

Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

Open the price desk →

More in Evidence